$6.91 -0.65 (-8.60%)
11/6/2009 4:00 PM

Jazz Pharmaceuticals, Inc. (JAZZ)

CAPS Rating: 1 out of 5

A specialty pharmaceutical company, which focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

Results 1 - 10 of 10

Recs

0
Member Avatar Hook5351 (< 20) Submitted: 9/8/2009 8:33:08 PM : Outperform Start Price: $8.96 JAZZ Score: -27.39

Rumor has it JAZZ may taken over buy Forrest Labs

Recs

0
Member Avatar Snowpro1 (< 20) Submitted: 9/6/2009 1:08:04 PM : Outperform Start Price: $8.96 JAZZ Score: -27.39

Insiders /Phase 111

Recs

0
Member Avatar michaeltbryant (< 20) Submitted: 9/5/2009 10:44:35 PM : Outperform Start Price: $8.96 JAZZ Score: -27.39

Hm...............insider bought 1.5 million shares.

Recs

0
Member Avatar yaodao (< 20) Submitted: 8/28/2009 12:17:09 PM : Outperform Start Price: $6.98 JAZZ Score: -5.80

Japanese Candlestick

Recs

0
Member Avatar keithtarbi (29.60) Submitted: 8/24/2009 10:55:15 AM : Outperform Start Price: $6.25 JAZZ Score: +6.89

Great stock..new drug offering!!!

Recs

0
Member Avatar mlb1232000 (31.46) Submitted: 8/12/2009 8:50:15 AM : Outperform Start Price: $7.82 JAZZ Score: -19.76

Earnings report last night. Good report.

Recs

0
Member Avatar LexTNZorro (75.94) Submitted: 6/19/2009 10:36:49 PM : Outperform Start Price: $3.39 JAZZ Score: +85.73

http://seekingalpha.com/article/143384-fda-calendar-updates-transdel-javelin-jazz-par-pharma?source=feed

Recs

5
Member Avatar TSIF (98.51) Submitted: 6/18/2009 3:22:40 PM : Outperform Start Price: $3.13 JAZZ Score: +102.15

JAZZ Pharmaceuticals stopped playing the blues after Phase III data was released indicating it'ssodium oxybate (JZP-6) showed a statistically significant reduction in fibromyalgia pain. Since the drug is already marketed to treat narcolepsy (a chronic sleep disorder), the safety concern of the two major issues for approval, (safety and affectivity) should be minimal. JAZZ soard as high as $4.85 as is typical on drug stocks with good news lately. The pullback to the low $3's in my opinion is a gift. Yes drug stocks are highly volitile. Funding, results, approvals, all cause gyrations. It is becoming harder to buy a drug between Phase III and FDA approval/disapproval with a decent risk reward as speculators abound. I think JAZZ has a good valuation. To have only been in business since 2003, Jazz's portfolio of neurology and psychiatry drugs/candidates has some great potential. I'm JAZZ'd up on JAZZ.

Recs

0
Member Avatar geodawg2000 (< 20) Submitted: 6/16/2009 10:41:38 PM : Underperform Start Price: $3.77 JAZZ Score: -65.11

this was too quick of a run. Especially only after a trail run.

Recs

0
Member Avatar svande8952 (< 20) Submitted: 6/16/2009 11:07:53 AM : Underperform Start Price: $4.10 JAZZ Score: -51.77

Steep run up recently looks good for red thumb and their cash position is 1/3 of what it was 2 quarters ago

Results 1 - 10 of 10

Featured Broker Partners